Physician profile
Carlos E Guzman
NPI 1225028442
$1,093.18
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $424 · 2023: $124 · 2024: $97.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.67 | 2021-2023 | Farxiga |
| Amgen INC. | $186.65 | 2022-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $67.62 | 2022 | |
| Abbvie INC. | $60.61 | 2021-2022 | |
| Novo Nordisk INC | $59.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.33 | 2021 | |
| Mannkind Corporation | $54.87 | 2021 | |
| Pfizer INC. | $54.37 | 2021-2024 | |
| Lilly USA, LLC | $44.98 | 2021-2024 | Mounjaro |
| Mylan Specialty L.P. | $40.96 | 2021 | |
| Sunovion Pharmaceuticals INC. | $37.71 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $32.09 | 2022 | |
| Abbott Laboratories | $30.67 | 2021 | |
| Alkermes, INC. | $29.16 | 2024 | Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $22.79 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.03 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.78 | 2021 | |
| Neurelis, INC. | $19.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.95 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.37 | 2021 | |
| Glaxosmithkline, LLC. | $16.96 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.